

- B3
- (e) a fragment or conservative amino acid substitution variant of a peptide of
(a), (b), (c) or (d).
-

Please add new claims 27-37 as follows:

--27. An antibody according to claim 25 specific for a peptide selected from the
group consisting of

- B4
- (a) VSHGFTEQN (Sequence ID NO:2);
 - (b) HGFTEQNSG (Sequence ID NO:3);
 - (c) FTEQNSGLI (Sequence ID NO:4);
 - (d) EQNSGLIYR (Sequence ID NO:5);
 - (e) NSGLIYRGQ (Sequence ID NO:6);
 - (f) GLIYRGQSG (Sequence ID NO:7);
 - (g) IYRGQSGGM (Sequence ID NO:8);
 - (h) RGQSGGMNE (Sequence ID NO:9); and
 - (i) QSGGMNEAF (Sequence ID NO:10).

28. An antibody according to claim 25 specific for the peptide HGFTEQNSG
(Sequence ID NO:3).

29. An antibody according to claim 25 specific for the peptide RYMDQPSRD
(Sequence ID NO:14).

30. The antibody of claim 28 wherein the antibody is a monoclonal antibody.

31. The antibody of claim 28 wherein the antibody is a polyclonal antibody.

32. The antibody of claim 29 wherein the antibody is a monoclonal antibody.

33. The antibody of claim 29 wherein the antibody is a polyclonal antibody.

34. An antiserum comprising an antibody in accordance with claim 28.

35. An antiserum comprising an antibody in accordance with claim 29.

36. A method of treating a lung infection in a subject caused by a bacterial pathogen which secretes a zinc metalloprotease, said method comprising administering to the subject an effective amount of the antibody of claim 28.

37. A method of treating a lung infection in a subject caused by a bacterial pathogen which secretes a zinc metalloprotease, said method comprising administering to the subject an effective amount of the antibody of claim 29.--
